During the SelectCCS process, a small sample of genetic material (~5 cells) is safely biopsied from the trophectoderm layer of the embryo during the blastocyst stage of development, when the embryo consists of 200 or more cells.

Once in the lab, the genetic material (DNA) is amplified using realtime polymerase chain reaction (qPCR) technology, and sophisticated bioinformatics algorithms applied to precisely determine the molecular karyotype or chromosomes of the embryo.

By the end of the SelectCCS process providers and patients can make better decisions about which embryos should be considered for IVF transfer based on their chromosomal make up.